MX2021014361A - Nuevos compuestos para la inhibición de janus quinasa 1. - Google Patents

Nuevos compuestos para la inhibición de janus quinasa 1.

Info

Publication number
MX2021014361A
MX2021014361A MX2021014361A MX2021014361A MX2021014361A MX 2021014361 A MX2021014361 A MX 2021014361A MX 2021014361 A MX2021014361 A MX 2021014361A MX 2021014361 A MX2021014361 A MX 2021014361A MX 2021014361 A MX2021014361 A MX 2021014361A
Authority
MX
Mexico
Prior art keywords
inhibition
novel compounds
janus kinase
compounds
janus
Prior art date
Application number
MX2021014361A
Other languages
English (en)
Inventor
Himanshu Rai
Anil Kumar
Sazid Ali
Srinivasa Reddy Bapuram
Santosh Kumar Rai
Mahadev Bandgar
Amol Pandurang Gunjal
Rakesh Iswar Patil
Original Assignee
Mankind Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mankind Pharma Ltd filed Critical Mankind Pharma Ltd
Publication of MX2021014361A publication Critical patent/MX2021014361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un objeto de la invención es proporcionar compuestos como inhibidores selectivos de JAK1, un proceso para la preparación de los inhibidores, una composición que contiene los compuestos y la utilidad de los compuestos.
MX2021014361A 2019-05-28 2020-05-26 Nuevos compuestos para la inhibición de janus quinasa 1. MX2021014361A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201911021098 2019-05-28
PCT/IN2020/050471 WO2020240586A1 (en) 2019-05-28 2020-05-26 Novel compounds for inhibition of janus kinase 1

Publications (1)

Publication Number Publication Date
MX2021014361A true MX2021014361A (es) 2022-04-06

Family

ID=73553608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014361A MX2021014361A (es) 2019-05-28 2020-05-26 Nuevos compuestos para la inhibición de janus quinasa 1.

Country Status (10)

Country Link
US (1) US20220235046A1 (es)
EP (1) EP3976612A4 (es)
JP (1) JP2022534510A (es)
AU (1) AU2020284742A1 (es)
BR (1) BR112021023635A2 (es)
CA (1) CA3141571A1 (es)
MX (1) MX2021014361A (es)
TW (1) TWI839524B (es)
WO (1) WO2020240586A1 (es)
ZA (1) ZA202109183B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021237111A1 (en) * 2020-05-21 2021-11-25 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
TW202245774A (zh) * 2021-02-05 2022-12-01 大陸商上海齊魯製藥研究中心有限公司 嘧啶或吡啶並雜環類腺苷受體抑制劑及其製備方法和用途
CA3214088A1 (en) * 2021-05-06 2022-11-10 Peter Ray Pkc-theta modulators
CN118510757A (zh) * 2021-12-22 2024-08-16 伊卡根有限责任公司 环丙基化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534796B2 (en) * 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
EA201001224A1 (ru) * 2008-02-04 2011-08-30 Цитокинетикс, Инкорпорейтед Химические соединения, композиции и способы их использования
CA2728559A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
FI124118B (fi) * 2011-06-13 2014-03-31 Reijo Uolevi Hautalahti Aurinkoenergian avulla sähköä ja lämpöä tuottava voimala
WO2013116291A1 (en) * 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN105837572B (zh) * 2015-02-02 2019-04-19 四川大学 N-取代苯基酰胺衍生物及其制备方法和用途
CN106146504B (zh) * 2015-04-17 2018-09-07 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
EP3360878B9 (en) * 2015-12-11 2021-05-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
CN109641892B (zh) * 2016-08-16 2021-07-02 默克专利有限公司 用作可逆btk抑制剂的2-氧代-咪唑并吡啶及其用途
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途

Also Published As

Publication number Publication date
US20220235046A1 (en) 2022-07-28
AU2020284742A1 (en) 2022-02-03
TW202110838A (zh) 2021-03-16
CA3141571A1 (en) 2020-12-03
EP3976612A1 (en) 2022-04-06
BR112021023635A2 (pt) 2022-02-01
JP2022534510A (ja) 2022-08-01
CN114174294A (zh) 2022-03-11
TWI839524B (zh) 2024-04-21
WO2020240586A1 (en) 2020-12-03
ZA202109183B (en) 2022-08-31
EP3976612A4 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
MX2021014361A (es) Nuevos compuestos para la inhibición de janus quinasa 1.
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
MX2023001917A (es) Inhibidores de la fosfatasa shp2 y metodos para su uso.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
TN2010000131A1 (en) Polo-like kinase inhibitors
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
MY194364A (en) Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof
PH12021550743A1 (en) Boron containing pde4 inhibitors
MX2022004035A (es) Inhibidor de diacilglicerol aciltransferasa 2.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2022006281A (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
MX2022001467A (es) Derivados quinolina como inhibidores de proteína quinasa.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2020014276A (es) Compuestos policiclicos como inhibidores de epoxido hidrolasa soluble.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
WO2021076817A3 (en) Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2
MX2023000198A (es) Inhibidores de atr y usos de estos.
CR20220551A (es) Procesos para la preparación de un inhibidor de cinasa
MX2022006370A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso.
MX2020007342A (es) Compuestos de sililetinilo hetarilo como inhibidores de la nitrificacion.
MX2021004288A (es) Nuevo proceso para la sintesis de derivados de piperazinil-etoxi-bromofenilo y su aplicacion en la produccion de compuestos que los contienen.
MX2023010606A (es) Formas de sales y sólidas de un inhibidor de cinasas.
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
WO2021138331A3 (en) Small molecule inhibitors of ulk1